0000000000563607
AUTHOR
Tim O'brien
X-RAY SPECTROSCOPIC DIAGNOSIS OF A WIND-COLLIMATED BLAST WAVE AND METAL-RICH EJECTA FROM THE 2006 EXPLOSION OF RS OPHIUCHI
Chandra HETG observations of RS Ophiuchi at day 13.9 of the 2006 outburst reveal a rich spectrum of emission lines from abundant ions formed over a wide temperature range (∼ 3 × 10 6 to 60 × 10 6 K) indicative of shock heating of the circumstellar medium by the expanding blast wave. Lines are asymmetric and strongly broadened (v ∼ 2400 km s −1 at zero intensity). Using simple analytical model profiles, we show how the lines are shaped by differential absorption in the red giant wind and explosion ejecta, and that shock heating to multimillion degree temperatures appears to have occurred preferentially in the direction perpendicular to the line of sight. We conclude that the asymmetric natur…
RANDOMIZED PHASE II STUDY OF FIRST-LINE EVEROLIMUS (EVE) + BEVACIZUMAB (BEV) VERSUS INTERFERON ALFA-2A (IFN) + BEV IN PATIENTS (PTS) WITH METASTATIC RENAL CELL CARCINOMA (MRCC): RECORD-2
ABSTRACT Background Study results demonstrated that IFN augments BEV activity and improves median PFS in pts with mRCC. Thus, combination BEV + IFN is a standard first-line treatment option for mRCC. Combining BEV with the mTOR inhibitor EVE may be an efficacious and well-tolerated treatment option. The open-label, phase II RECORD-2 trial compared first-line EVE + BEV and IFN + BEV in mRCC. Patients and methods: Therapy-naive pts with clear cell mRCC and prior nephrectomy were randomized 1:1 to BEV 10 mg/kg IV every 2 weeks with either EVE 10 mg oral daily or IFN (9 MIU SC 3 times/week, if tolerated). Tumour assessments were every 12 weeks. Primary objective was treatment effect on progress…